Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

ClinicalTrials.gov ID: NCT05695391

Public ClinicalTrials.gov record NCT05695391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures

Study identification

NCT ID
NCT05695391
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Enrollment
2 participants

Conditions and interventions

Conditions

Interventions

  • Coagulation Factor VIIa (Recombinant) Biological

Biological

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 6, 2024
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update posted
Jul 8, 2025

2024 – 2025

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Orthopaedic Institute for Children - Orthopaedic Hemophilia Treatment Center Los Angeles California 90007
Children's Healthcare of Atlanta Atlanta Georgia 30322
Tulane Univertsity School of Medecine New Orleans Louisiana 70112
M Health Fairview Center for bleeding and Clotting disorders Minneapolis Minnesota 55455
University of Texas Health Science Center at Houston Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05695391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 8, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05695391 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →